Page last updated: 2024-09-05

melagatran and Obesity

melagatran has been researched along with Obesity in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Eriksson, UG; Homolka, R; Peters, GR; Sarich, TC; Svensson, M; Teng, R; Wollbratt, M1

Trials

1 trial(s) available for melagatran and Obesity

ArticleYear
No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
    Clinical pharmacokinetics, 2003, Volume: 42, Issue:5

    Topics: Administration, Oral; Adult; Area Under Curve; Azetidines; Benzylamines; Female; Glycine; Half-Life; Humans; Inactivation, Metabolic; Male; Obesity; Thrombin

2003